Skip to content
15% off your first order15% off your first order

Semaglutide vs Tirzepatide

Semaglutide and Tirzepatide are both incretin-based compounds studied in metabolic research, and both have been investigated as once-weekly subcutaneous agents. Semaglutide is a long-acting GLP-1 receptor agonist whose structural modifications extend its half-life. Research has examined its role in glucose-dependent insulin signaling, gastric emptying, satiety pathways, and weight loss in obesity without diabetes. Tirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors, and research asks whether adding the GIP component differs from GLP-1 agonism alone. Its phase 3 program has examined glycemic control in type 2 diabetes, weight reduction and maintenance in adults with obesity, and a head-to-head comparison with semaglutide in SURPASS-2.